Blue Matter Blog

What does COMPASS Pathways’ recent data on psilocybin mean for psychedelic therapies?
November 30, 2021

In early November of 2021, COMPASS Pathways released phase IIb data on its psilocybin-based therapy for treatment-resistant depression. Varun Renjen, M.D., leader of our CNS team, talks about this data and its implications for COMPASS (and for psychedelics in CNS therapy overall).

Towards Cancer Cures and Chronic Management: Key Trends and Their Commercial Implications

Introduction Over the last decade, advances in cancer care have measurably improved overall survival, and specifically in disease areas with previously high unmet needs such as non-small cell lung cancer (NSCLC) and melanoma1. Importantly, this increased survival is driven by a shift of more patients into two key categories of treatment outcomes: Cure: Defined here …

12 Pitfalls in Europe: Pitfall #5 – Thinking your list price won’t cross borders
November 10, 2021

At some point, any growth-minded non-European biopharma company will look to Europe as a possible source of new opportunity.  Europe is attractive and offers vast market potential. But successfully entering Europe is a complex undertaking.  The stakes are high and there are many pitfalls to avoid.  In this series of articles, we’re outlining the 12 …

12 Pitfalls in Europe: Pitfall #4 – Believing EMA marketing authorization = patient access
November 4, 2021

At some point in its development, any growth-minded non-European biopharma company will look to Europe as a possible source of new opportunity.  Europe is attractive for various reasons, including its large population, high per-capita spend on healthcare, and vast market potential. But successfully entering Europe is a complex undertaking, and biopharma companies need to know …